JNJ
NYSEJohnson & Johnson
Revenue and Net Income
Values in USD
Income Statement
Values in USD
| Financial item | TTMJun 30, 2026 | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|---|
Total Revenue | 97.93B | 94.19B | 88.82B | 85.16B | 79.99B |
Cost of Revenue | 31.43B | 30.26B | 27.47B | 26.55B | 24.60B |
Gross Profit | 66.50B | 63.94B | 61.35B | 58.61B | 55.39B |
Operating Expense | 40.24B | 38.34B | 40.10B | 36.60B | 34.38B |
Operating Income | 26.26B | 25.60B | 21.25B | 22.01B | 21.01B |
Net Non Operating Interest Income Expense | -100.00M | 85.00M | 577.00M | 489.00M | 214.00M |
Other Income Expense | -1.96B | 6.89B | -5.14B | -7.44B | -1.87B |
Pretax Income | 25.20B | 32.58B | 16.69B | 15.06B | 19.36B |
Tax Provision | 4.16B | 5.78B | 2.62B | 1.74B | 2.99B |
Net Income Common Stockholders | 21.04B | 26.80B | 14.07B | 35.15B | 17.94B |
Diluted NI Available to Com Stockholders | 21.04B | 26.80B | 14.07B | 35.15B | 17.94B |
Basic EPS | 8.73 | 11.13 | 5.84 | 14.60 | 6.86 |
Diluted EPS | 8.62 | 11.03 | 5.79 | 13.72 | 6.73 |
Basic Average Shares | 2.41B | 2.41B | 2.41B | 2.41B | 2.61B |
Diluted Average Shares | 2.44B | 2.43B | 2.43B | 2.56B | 2.66B |
Total Expenses | 71.67B | 68.60B | 67.57B | 63.15B | 58.98B |
Net Income from Continuing & Discontinued Operation | 21.04B | 26.80B | 14.07B | 35.15B | 17.94B |
Normalized Income | 22.31B | 21.96B | 20.00B | 14.04B | 17.27B |
Interest Income | — | 1.06B | 1.33B | 1.26B | 490.00M |
Interest Expense | — | 971.00M | 755.00M | 772.00M | 276.00M |
Net Interest Income | -100.00M | 85.00M | 577.00M | 489.00M | 214.00M |
EBIT | 26.49B | 33.55B | 17.44B | 15.83B | 19.64B |
EBITDA | 26.49B | 41.05B | 24.78B | 23.32B | 26.61B |
Reconciled Cost of Revenue | 31.43B | 30.26B | 27.47B | 26.55B | 24.60B |
Reconciled Depreciation | — | 7.50B | 7.34B | 7.49B | 6.97B |
Net Income from Continuing Operation Net Minority Interest | 21.04B | 26.80B | 14.07B | 13.33B | 16.37B |
Total Unusual Items Excluding Goodwill | -1.53B | 5.89B | -7.04B | -802.00M | -1.06B |
Total Unusual Items | -1.53B | 5.89B | -7.04B | -802.00M | -1.06B |
Normalized EBITDA | 28.02B | 35.16B | 31.83B | 24.12B | 27.66B |
Tax Rate for Calcs | 0.17 | 0.18 | 0.16 | 0.12 | 0.15 |
Tax Effect of Unusual Items | -252.55M | 1.04B | -1.11B | -92.23M | -162.93M |
Key Statistics
Valuation
Volume & Shares
Growth Indicators
Currency & Exchange
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies breast aesthetics and reconstruction contact lenses under the ACUVUE brand intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.